BioAscent and XenoGesis work together to combine their capabilities and expertise across the key disciplines of in vitro biosciences, DMPK and Medicinal Chemistry.
Using a tailored, iterative design-make-test approach, we work from target validation onwards to develop a compound for candidate nomination.
Our combined track record and specific experience in generating quality hit and lead series that have maximum chance of success in Lead Optimisation and beyond is unrivalled.
XenoGesis is a laboratory-based contract research organisation specialising in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling & simulation for human PK and dose prediction. The core XenoGesis team has a proven track record in drug discovery.
XenoGesis’ validated laboratory assays build a full picture of the ADME properties of a molecule including required human drug exposure, backed-up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’.
Through a consultative approach, XenoGesis helps to identify the potential ‘winners’ and ‘losers’ in the compounds synthesised throughout a drug discovery campaign, providing significant time and cost savings for clients. Providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis. The organisation combines its state-of-the-art in vitro, in vivo and bioanalytical capabilities with its expert pharmacokinetic/ pharmacodynamic (PK/PD) data interpretation services with GastroPlus™.